Literature DB >> 23929239

[Vaccination in adult patients with chronic inflammatory rheumatic diseases].

S Goldacker1, A M Gause, K Warnatz.   

Abstract

Patients with chronic inflammatory rheumatic diseases often have an intrinsic and therapy associated increased susceptibility to infections which substantially contributes to morbidity and mortality of the patients. A large proportion of these infections are preventable by vaccination. For this reason in 2005 the standing vaccination committee (STIKO) recommended for patients with immunosuppression vaccination against pneumococcus, influenza, Haemophilus influenza b and meningococcus in addition to standard vaccinations, independent of age. Every patient should therefore be informed about a possible increase in susceptibility to infections and the recommended prevention by vaccination before implementation of immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23929239     DOI: 10.1007/s00393-013-1155-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  78 in total

1.  The humoral immune response to influenza vaccination in lung transplant patients.

Authors:  P J Mazzone; S B Mossad; S D Mawhorter; A C Mehta; R J Schilz; J R Maurer
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

2.  Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.

Authors:  Ori Elkayam; Sharon Amir; Ella Mendelson; Mitchell Schwaber; Itamar Grotto; Jonathan Wollman; Uri Arad; Ayelet Brill; Daphna Paran; David Levartovsky; Irena Wigler; Dan Caspi; Michal Mandelboim
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-07       Impact factor: 4.794

3.  Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.

Authors:  M C Kapetanovic; T Saxne; J-A Nilsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2006-11-18       Impact factor: 7.580

4.  Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.

Authors:  L B S Gelinck; Y K O Teng; G F Rimmelzwaan; B J F van den Bemt; F P Kroon; J M van Laar
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

5.  Hepatitis B vaccine side-effect.

Authors:  Y Carmeli; R Oren
Journal:  Lancet       Date:  1993-01-23       Impact factor: 79.321

6.  [Infections in systemic lupus erythematosus].

Authors:  L Massardo; M E Martínez; M Baro; F Figueroa; S Rivero; S Jacobelli
Journal:  Rev Med Chil       Date:  1991-10       Impact factor: 0.553

7.  Rituximab treatment results in impaired secondary humoral immune responsiveness.

Authors:  Lizet E van der Kolk; Joke W Baars; Martin H Prins; Marinus H J van Oers
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.

Authors:  Marloes W Heijstek; Gecilmara C S Pileggi; Evelien Zonneveld-Huijssoon; Wineke Armbrust; Esther P A H Hoppenreijs; Cuno S P M Uiterwaal; Wietse Kuis; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

9.  Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.

Authors:  Sudha Visvanathan; Gregory F Keenan; Daniel G Baker; Arnold I Levinson; Carrie L Wagner
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

10.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01
View more
  10 in total

Review 1.  [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

Authors:  F Behrens; D Thaçi; J Wollenhaupt; K Krüger
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

Review 2.  [Choosing wisely recommendations in rheumatology : One year after their first publication].

Authors:  E Märker-Hermann; A J Voormann
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

Review 3.  [B cell therapy of rheumatoid arthritis with rituximab. Practice-relevant aspects for the routine].

Authors:  M Schmalzing; H-P Tony
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

4.  Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic.

Authors:  Marco Krasselt; Jean-Philipp Ivanov; Christoph Baerwald; Olga Seifert
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

Review 5.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

6.  Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic.

Authors:  M Krasselt; C Baerwald; O Seifert
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

7.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

8.  [Prophylaxis and treatment of infections in elderly patients with rheumatism].

Authors:  C Kneitz; A Strangfeld; K Krüger
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

Review 9.  [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

Authors:  F Behrens; D Thaçi; J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2016-06       Impact factor: 1.372

10.  [How well are patients with inflammatory rheumatic diseases protected against measles?]

Authors:  U Kiltz; A Celik; S Tsiami; X Baraliakos; I Andreica; D Kiefer; B Bühring; J Braun
Journal:  Z Rheumatol       Date:  2020-09-15       Impact factor: 1.372

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.